Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids

Journal of Thoracic and Cardiovascular Surgery

Volumn 149, Issue 5, 2015, Pages 1417-1425.e1

  Lei, Hongyi ^a,b   Hofferberth, Sophie C ^a   Liu, Rong ^a   Colby, Aaron ^c   Tevis, Kristie M ^c   Catalano, Paul ^a   Grinstaff, Mark W ^c   Colson, Yolonda L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c BOSTON UNIVERSITY   (United States)

Author keywords

mesothelioma; nanoparticle; paclitaxel; spheroids

Indexed keywords

CASPASE 3; DEOXYGLUCOSE; NANOPARTICLE; PACLITAXEL; PROPIDIUM IODIDE; SODIUM AZIDE; WORTMANNIN; ALCOHOL; ANTINEOPLASTIC AGENT; CARBOXYLIC ACID; CREMOPHOR; EXCIPIENT; FLUORESCENT DYE; GLYCEROL; OREGON GREEN 488 CARBOXYLIC ACID; RHODAMINE; RHODAMINE B;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONFOCAL MICROSCOPY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MALIGNANT MESOTHELIOMA; MULTICELLULAR SPHEROID; PINOCYTOSIS; PRIORITY JOURNAL; TUMOR SPHEROID; UPREGULATION; ANALOGS AND DERIVATIVES; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; KINETICS; LUNG TUMOR; MEDICINAL CHEMISTRY; MESOTHELIOMA; METABOLISM; NANOMEDICINE; PATHOLOGY; PHARMACEUTICS; PROCEDURES; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARBOXYLIC ACIDS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; EXCIPIENTS; FLUORESCENT DYES; GLYCEROL; HUMANS; KINETICS; LUNG NEOPLASMS; MESOTHELIOMA; MICROSCOPY, CONFOCAL; NANOMEDICINE; NANOPARTICLES; PACLITAXEL; PINOCYTOSIS; RHODAMINES; SPHEROIDS, CELLULAR; TECHNOLOGY, PHARMACEUTICAL;

EID: 84929607063     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2015.02.020     Document Type: Article

References (33)

1. A.P. Griset, J. Walpole, R. Liu, A. Gaffey, Y.L. Colson, and M.W. Grinstaff Expansile nanoparticles: synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system J Am Chem Soc 131 2009 2469 2471
2. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nature Nanotechnol 2 2007 751 760
3. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov Today 8 2003 1112 1120
4. S. Vijayaraghavalu, D. Raghavan, and V. Labhasetwar Nanoparticles for delivery of chemotherapeutic agents to tumors Curr Opin Investig Drugs 8 2007 477 484
5. G. Zhang, X. Zeng, and P. Li Nanomaterials in cancer-therapy drug delivery system J Biomed Nanotechnol 9 2013 741 750
6. Y.L. Colson, R. Liu, E.B. Southard, M.D. Schulz, J.E. Wade, and A.P. Griset The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis Biomaterials 32 2011 832 840
7. B. Kim, G. Han, B.J. Toley, C.K. Kim, V.M. Rotello, and N.S. Forbes Tuning payload delivery in tumour cylindroids using gold nanoparticles Nature Nanotechnol 5 2010 465 472
8. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat Rev Cancer 6 2006 583 592
9. A. Birgersdotter, R. Sandberg, and I. Ernberg Gene expression perturbation in vitro - a growing case for three-dimensional (3D) culture systems Semin Cancer Biol 15 2005 405 412
10. I. Dufau, C. Frongia, F. Sicard, L. Dedieu, P. Cordelier, and F. Ausseil Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer BMC Cancer 12 2012 15
11. B. Fallica, G. Makin, and M.H. Zaman Bioengineering approaches to study multidrug resistance in tumor cells Integrat Biol 3 2011 529 539
12. R.M. Sutherland, J.A. McCredie, and W.R. Inch Growth of multicell spheroids in tissue culture as a model of nodular carcinomas J Natl Cancer Inst 46 1971 113 120
13. G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker, and S. Takayama Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy J Control Release 164 2012 192 204
14. A.H. Colby, Y.L. Colson, and M.W. Grinstaff Microscopy and tunable resistive pulse sensing characterization of the swelling of pH-responsive, polymeric expansile nanoparticles Nanoscale 5 2013 3496 3504
15. J. Friedrich, C. Seidel, R. Ebner, and L.A. Kunz-Schughart Spheroid-based drug screen: considerations and practical approach Nature Protoc 4 2009 309 324
16. S. Huo, H. Ma, K. Huang, J. Liu, T. Wei, and S. Jin Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors Cancer Res 73 2013 319 330
17. D. Gilmore, M. Schulz, R. Liu, K.A. Zubris, R.F. Padera, and P.J. Catalano Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma Ann Surg Oncol 20 2013 1684 1693
18. K.A. Zubris, R. Liu, A. Colby, M.D. Schulz, Y.L. Colson, and M.W. Grinstaff In vitro activity of Paclitaxel-loaded polymeric expansile nanoparticles in breast cancer cells Biomacromolecules 14 2013 2074 2082
19. S. Tomek, S. Emri, K. Krejcy, and C. Manegold Chemotherapy for malignant pleural mesothelioma: past results and recent developments Br J Cancer 88 2003 167 174
20. J. Van Meerbeeck, C. Debruyne, N. van Zandwijk, P.E. Postmus, M.C. Pennucci, and F. van Breukelen Paclitaxel for malignant pleural mesothelioma: a Phase II study of the EORTC Lung Cancer Cooperative Group Br J Cancer 74 1996 961 963
21. P. Ellis, A.M. Davies, W.K. Evans, A.E. Haynes, N.S. Lloyd Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline J Thorac Oncol 1 2006 591 601
22. C.J. Linden, C. Mercke, U. Albrechtsson, L. Johansson, and S.B. Ewers Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study Eur Respir J 9 1996 2565 2572
23. G. Hamilton Multicellular spheroids as an in vitro tumor model Cancer Lett 131 1998 29 34
24. X. Zhen, X. Wang, C. Xie, W. Wu, and X. Jiang Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles Biomaterials 34 2013 1372 1382
25. G. Gu, X. Gao, Q. Hu, T. Kang, Z. Liu, and M. Jiang The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells Biomaterials 34 2013 5138 5148
26. X. Wang, X. Zhen, J. Wang, J. Zhang, W. Wu, and X. Jiang Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles Biomaterials 34 2013 4667 4679
27. R. Liu, D.M. Gilmore, K.A. Zubris, X. Xu, P.J. Catalano, and R.F. Padera Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles Biomaterials 34 2013 1810 1819
28. S. Falcone, E. Cocucci, P. Podini, T. Kirchhausen, E. Clementi, and J. Meldolesi Macropinocytosis: regulated coordination of endocytic and exocytic membrane traffic events J Cell Sci 119 Pt 22 2006 4758 4769
29. M.C. Kerr, and R.D. Teasdale Defining macropinocytosis Traffic 10 2009 364 371
30. A. Rupper, K. Lee, D. Knecht, and J. Cardelli Sequential activities of phosphoinositide 3-kinase, PKB/Aakt, and Rab7 during macropinosome formation in dictyostelium Mol Biol Cell 12 2001 2813 2824
31. J.L. Au, D. Li, Y. Gan, X. Gao, A.L. Johnson, and J. Johnston Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention Cancer Res 58 1998 2141 2148
32. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, and A. Yang Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 2006 1317 1324
33. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, and A. Yang Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11 2005 4136 4143